Logan P M, Whitney S, Naiman S, Levy J G
Department of Microbiology, University of British Columbia, Vancouver, Canada.
Leuk Res. 1988;12(1):19-24. doi: 10.1016/s0145-2126(98)80004-0.
A leukemia-associated antigen, CAMAL, shown to be present in bone marrow (BM) cells from patients with acute nonlymphoblastic leukemia (ANLL) even during remission, has been examined using indirect immunoperoxidase and a monoclonal antibody, CAMAL-1. We are ending the third year of an ongoing blind study designed to monitor the number of BM cells expressing the CAMAL protein (CAMAL BM value) in ANLL patients over the course of their disease. Results thus far have revealed that the CAMAL BM value in individual patients often changed significantly post-chemotherapy. This change appeared to be a useful prognostic marker in many instances. ANLL patients at initial presentation whose CAMAL BM values increased or stayed the same post-chemotherapy had significantly (p less than 0.025) shorter remission lengths (x = 6.8 months, n = 24) than those whose CAMAL BM values decreased (x = 19.2 months, n = 10). There are indications that increasing CAMAL BM values during remission occur prior to clinical relapse.
一种与白血病相关的抗原，即CAMAL，已被证实即使在缓解期也存在于急性非淋巴细胞白血病（ANLL）患者的骨髓（BM）细胞中。我们使用间接免疫过氧化物酶法和单克隆抗体CAMAL-1对其进行了检测。我们正在进行一项为期三年的盲法研究，旨在监测ANLL患者在疾病过程中表达CAMAL蛋白的骨髓细胞数量（CAMAL BM值）。迄今为止的结果显示，个体患者的CAMAL BM值在化疗后常常发生显著变化。在许多情况下，这种变化似乎是一个有用的预后标志物。化疗后CAMAL BM值升高或保持不变的初诊ANLL患者，其缓解期（x = 6.8个月，n = 24）明显（p < 0.025）短于CAMAL BM值降低的患者（x = 19.2个月，n = 10）。有迹象表明，缓解期CAMAL BM值升高发生在临床复发之前。
